CLINICAL EFFECTS OF INCREASE IN THE LOADING DOSE OF TAMSULOSIN (FROM 0.2mg TO 0.3mg) ON URINARY DISTURBANCE ASSOCIATED WITH BENIGN PROSTATE HYPERPLASIA
Kawabe K, Ueno A, Takimoto Y, et al.: Use of an α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 144: 908-912, 1990
Abrams P, Speakman M, Stott M, et al.: A doseranging study of the efficacy and safely of tamsulosin, the first prostate-selective α1A -adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80: 587-596, 1997
Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51: 892-900, 1998